The pharmaceutical industry is demanding of experience and knowledge in the field for individuals to become great professionals. 20 years of experience is more than enough though, to be one of the most influential names in the area. In San Francisco, Jeanmarie Guenot is leading the pharmaceutical market through her company, the Amphivena Therapeutics. Amphivena has a very particular purpose: Developing innovative bifunctional antibody therapies for hematologic malignancies.

Guenot is the President and CEO of the company, and her two decades or more of experience, considering she was also a bright student of the subject, has brought her to having passed through many other companies in the pharmaceutical and biotechnology industry. Jeanmarie has built and rebuilt enterprises from the ground as well as helped partners grow.

Read more: Collaboration to Advance T-Cell Engagement Therapies

Her first start-up was the SKS Ocular company that wanted to deliver some technologies to assist in developing a therapy for glaucoma, macular degeneration, and ocular inflammation. It wasn’t the beginning of her career though, as she began working in Atlas Venture, managing investments, and capital towards other companies in the scientific areas on It wouldn’t be long before she decided to start building companies though, but she first went through Hoffmann-La Roche as a principal scientist.

Amphivena is currently developing ways to treat and address blood cancer through antibody therapy. They do it by using the patient’s immune system as the natural weapon and identifier of the carcinogenic cells in the blood veins. Through this treatment, they try to maintain the balance in the blood veins, and the therapies that they have been able to develop through research have brought a lot of advancement to medicine and the ongoing fight against cancer.

Jeanmarie Guenot has a very deep familiarity with the science of the human body and diseases, having gathered expertise and knowledge in ophthalmic and neurology diseases, autoimmune diseases, cardiovascular diseases, and oncology. The scientist is highly desired by other companies mainly because of her twenty years in the industry and the amount of expertise she can bring to the table.

In addition to Amphivena Therapeutics, she began working in 2014 with the Hoffmann-La Roche and have assisted partners of her company through developing their researches, mainly including Janssen Biotech and Affimed Therapeutics.

Learn more about Jeanmarie Guenot: